biostudies-literatureDedrick RMJane and Aatos Erkko FoundationHoward Hughes Medical InstituteCystic Fibrosis FoundationBurroughs Wellcome FundNIAID NIH HHSNHLBI NIH HHSNational Heart, Lung, and Blood InstituteNIHNIGMS NIH HHS103-112https://www.ebi.ac.uk/biostudies/studies/S-EPMC9825826biostudies-literatureUnknown76(1)<h4>Background</h4>Nontuberculous Mycobacterium infections, particularly Mycobacterium abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance. Bacteriophage therapy represents a potentially novel approach. Relatively few active lytic phages are available and there is great variation in phage susceptibilities among M. abscessus isolates, requiring personalized phage identification.<h4>Methods</h4>Mycobacterium isolates from 200 culture-positive patients with symptomatic disease were screened for phage susceptibilities. One or more lytic phages were identified for 55 isolates. Phages were administered intravenously, by aerosolization, or both to 20 patients on a compassioClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaPhage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease.PMC9825826NICK20Y2-SVC and NICK20Y2-OUTHATFUL19GOGM131729HL146228NICK20Y2-OUTR35 GM131729K08 HL139994R01 HL090991R01 HL146228K08 HL139994-01NICK20Y2-SVCK23 AI154546AI154546GT12053R01HL146228Little JSNick JAWhitney Brown ASkurnik MCristinziano MSolomon DAKhatami AHatfull GFWark PRobert George CRDedrick RMBelessis YIp WMalmivaara KHaidar GIredell JTupayachi Ortiz MGBenson CAMoscatelli ASmith BEDavidson RMMichalik DEFreeman KGvan Duin DGarcia CBWorth ARobinson PDCohen KAGainey AJacobs-Sera DSoothill JPolenakovik HMSpencer HMcMullan BJSchooley RTfalsePhage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease.<h4>Background</h4>Nontuberculous Mycobacterium infections, particularly Mycobacterium abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance. Bacteriophage therapy represents a potentially novel approach. Relatively few active lytic phages are available and there is great variation in phage susceptibilities among M. abscessus isolates, requiring personalized phage identification.<h4>Methods</h4>Mycobacterium isolates from 200 culture-positive patients with symptomatic disease were screened for phage susceptibilities. One or more lytic phages were identified for 55 isolates. Phages were administered intravenously, by aerosolization, or both to 20 patients on a compassio2023-01-01T00:00:00Z2023 Jan2026-04-08T16:08:39.045Z2025-04-06T11:43:28.136ZS-EPMC98258263567682310.1093/cid/ciac453